John Neylan Insider Profile
4 Followers
John Neylan, EVP, Chief Medical Officer and Head of Research at Elicio Therapeutics, holds 35.14K shares in Elicio Therapeutics (Ticker: ELTX), holds 0.00 shares in Keryx Biopharma (Ticker: KERX).
John Neylan's Trading History
| ELTXElicio Therapeutics | Dec 21, 2021 | EVP, Chief Medical Officer and Head of Research | Uninformative Sell | 937.96 | $52.70K | |
| KERXKeryx Biopharma | Dec 13, 2018 | ― | Uninformative Sell | ― | $0.00 |
You May Also Like
John Neylan insider profile FAQ
What is the percentage of profitable transactions made by John Neylan?
The percentage of profitable transactions made by John Neylan is 77%.
What is the average return per transaction made by John Neylan?
The average return per transaction made by John Neylan is 21.40%.
What stocks does John Neylan hold?
John Neylan holds: ELTX, KERX stocks.
What was John Neylan’s latest transaction?
John Neylan’s latest transaction was an Uninformative Sell of $937.96.
What was John Neylan's most profitable transaction?
John Neylan’s most profitable transaction was an Informative Sell of ELTX stock on March 19, 2021. The return on the trade was 85.80%.
What is John Neylan's role in Elicio Therapeutics?
John Neylan's role in Elicio Therapeutics is EVP, Chief Medical Officer and Head of Research.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.
TipRanks measures corporate insiders by the stock transactions they report to the SEC. See how TipRanks ranks experts and calculates performance.
